Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-DC1 Vaccine + Androgen Ablation in Recurrent Prostate Cancer
NCT00970203Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2009
- Primary completion
- Oct 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-type-1-polarized dendritic cell vaccine in prostate cancer (PCa), sponsored by Roswell Park Comprehensive Cancer Center. Started Sep 2009; status: completed.
02
Drugs
alpha-type-1-polarized dendritic cell vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00970203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00970203.